Special Issue

The Therapeutic Potential of Neurotrophin Signaling in Neurodegenerative Disorders

Message from the Guest Editors

Since the first description of neurotrophins in the 1950s, these factors have been recognized as key regulators of central nervous system (CNS) homeostasis and promising therapeutic targets for neurodegenerative disorders. Neurotrophins-including NGF, BDNF, and NT-3/4—modulate multiple processes throughout development and adulthood, primarily through Trk and p75NTR receptor signaling. Imbalanced neurotrophin levels and dysfunctional neurotrophin receptors have been implicated in several CNS diseases, including Alzheimer's disease. Parkinson's disease, and multiple sclerosis. In this context, considerable efforts have been made to develop therapeutic strategies targeting neurotrophin signaling, including gene therapies and the modulation of neurotrophin receptor activity using synthetic small molecules.

This Special Issue aims to collect research articles and reviews that illuminate the mechanisms by which neurotrophin signaling contributes to neurodegenerative conditions, the challenges associated with targeting neurotrophin receptors, and the opportunities offered by gene therapies and other emerging therapeutic approaches.

Guest Editors

Dr. Konstantina Chanoumidou

Dr. Ioannis Charalampopoulos

Dr. Vasiliki Panagiotakopoulou

Deadline for manuscript submissions

30 April 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/259179

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

